Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Difficult treatment issues in sarcoidosis.

R P Baughman1, J P Lynch

  • 1Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati, Cincinnati, OH 45267-0564, USA. baughmrp@ucmail.uc.edu

Journal of Internal Medicine
|February 18, 2003
PubMed
Summary

Sarcoidosis management involves careful decisions, as not all patients require treatment. For chronic or refractory cases, alternative therapies beyond corticosteroids are explored, including newer agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The St. George's Respiratory Questionnaire in Pulmonary Sarcoidosis.

Lung·2020
Same author

Measuring sarcoidosis around the world: Using the same ruler.

Revista portuguesa de pneumologia·2017
Same author

The Prognostic Importance of Bronchoalveolar Lavage Fluid CXCL9 During Minimal Acute Rejection on the Risk of Chronic Lung Allograft Dysfunction.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Sarcoidosis extent relates to molecular variability.

Clinical and experimental immunology·2017
Same author

Tadalafil therapy for sarcoidosis-associated pulmonary hypertension.

Pulmonary circulation·2017
Same author

Impact of Allograft Injury Time of Onset on the Development of Chronic Lung Allograft Dysfunction After Lung Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016

Area of Science:

  • Pulmonology
  • Immunology
  • Internal Medicine

Background:

  • Sarcoidosis management requires nuanced decision-making, as many patients do not need treatment.
  • Corticosteroid therapy for sarcoidosis presents challenges, including difficulty in discontinuation and potential toxicities.
  • A significant portion of patients, at least one-third, may never require treatment.

Purpose of the Study:

  • To review critical aspects of sarcoidosis management.
  • To discuss treatment strategies for chronic and refractory sarcoidosis.
  • To highlight the evolving therapeutic landscape for sarcoidosis.

Main Methods:

  • Review of current literature on sarcoidosis management.
  • Discussion of treatment options including corticosteroids, alternative agents, and novel therapies.

Related Experiment Videos

  • Analysis of patient subgroups and their specific management needs.

    • Main Results:

    • Not all sarcoidosis patients necessitate treatment; asymptomatic individuals may not benefit from therapy.
    • Established second-line treatments like methotrexate, azathioprine, and hydroxychloroquine have limitations in efficacy and toxicity.
    • Refractory sarcoidosis patients may respond to newer agents such as thalidomide and anti-tumor necrosis factor monoclonal antibodies.

    Conclusions:

    • Treatment decisions in sarcoidosis should be individualized, considering disease activity and patient status.
    • Alternative and novel therapies offer options for patients with chronic or refractory sarcoidosis.
    • Ongoing research is crucial for optimizing sarcoidosis management and addressing unmet needs.